An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.07.013
Abstract: Introduction: Type 1 insulin‐like growth factor receptor is deregulated in solid tumors. Cixutumumab, a monoclonal antibody that inhibits the activity of type 1 insulin‐like growth factor receptor, was investigated in combination with pemetrexed/cisplatin in the… read more here.
Keywords: cixutumumab; open label; cisplatin; pemetrexed cisplatin ... See more keywords
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.03.001
Abstract: This phase 2 portion of a phase 1/2 study examined the efficacy and safety of LY2603618, a selective checkpoint kinase 1 inhibitor, combined with pemetrexed and cisplatin (LY+Pem+Cis) in patients with advanced nonsquamous non-small cell… read more here.
Keywords: cis; pemetrexed cisplatin; cis arm; pem cis ... See more keywords
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma – the SKOPOS trial
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1457597
Abstract: ABSTRACT Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM).… read more here.
Keywords: phase; trial; response; pemetrexed cisplatin ... See more keywords
A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice compared with pemetrexed or cisplatin alone
Sign Up to like & getrecommendations! Published in 2023 at "Physiology"
DOI: 10.1152/physiol.2023.38.s1.5734918
Abstract: Pemetrexed is a cytostatic agent used to treat solid tumors and autoimmune diseases. Pemetrexed exerts its antineoplastic activity by multitargeted disruption of folate-dependent processes that mediate cell replication. Pemetrexed is now combined with cisplatin to… read more here.
Keywords: cisplatin combination; cisplatin alone; physiology; cisplatin ... See more keywords
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps8582
Abstract: TPS8582Background: For patients (pts) with stage IB (≥4cm)-IIIA Non-small-cell lung cancer (NSCLC), multi-modality therapy yields a modest improvement in 5 year post-surgical overall survival (OS),... read more here.
Keywords: cisplatin gemcitabine; gemcitabine induction; cisplatin pemetrexed; nivolumab plus ... See more keywords
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.02542
Abstract: PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether… read more here.
Keywords: time; cisplatin alone; malignant pleural; patients malignant ... See more keywords